Abstract
Vancomycin-resistant enterococci (VRE) are a serious threat to human health, with few treatment options being available. New therapeutics are urgently needed to relieve the health and economic burdens presented by VRE. A potential target for new therapeutics is the VanRS two-component system, which regulates the expression of vancomycin resistance in VRE. VanS is a sensor histidine kinase that detects vancomycin and in turn activates VanR; VanR is a response regulator that, when activated, directs expression of vancomycin-resistance genes. This review of VanRS examines how the expression of vancomycin resistance is regulated, and provides an update on one of the field’s most pressing questions: How does VanS sense vancomycin?
Funder
National Institutes of Health
Subject
Virology,Microbiology (medical),Microbiology
Reference248 articles.
1. Vancomycin: A History
2. Antibiotic therapy of bacterial endocarditis. VII. Vancomycin for acute micrococcal endocarditis; preliminary report;Geraci;Proc. Staff Meet. Mayo Clin.,1958
3. Some laboratory and clinical experiences with a new antibiotic, vancomycin;Geraci;Proc. Staff Meet. Mayo Clin.,1956
4. Vancomycin, a new antibiotic. II. In vitro antibacterial studies;McGuire;Antibiot. Annu.,1955
5. Vancomycin Ototoxicity in a Patient with Normal Renal Function
Cited by
32 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献